Camber Capital Management
Latest statistics and disclosures from Camber Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SPY, ZBH, BAX, HUM, CVS, and represent 59.35% of Camber Capital Management's stock portfolio.
- Added to shares of these 5 stocks: ICLR (+$44M), MRK (+$40M), UNH (+$31M), APLS (+$15M), BMRN (+$5.5M).
- Started 4 new stock positions in APLS, MRK, UNH, ICLR.
- Reduced shares in these 10 stocks: SPY (-$618M), PFE (-$189M), , ZBH (-$114M), HUM (-$104M), BAX (-$88M), CVS (-$83M), PTCT (-$76M), CI (-$66M), QGEN (-$56M).
- Sold out of its positions in CI, GMAB, IONS, MLTX, PTCT, XBI, SRPT, GPCR, TXG, QGEN.
- Camber Capital Management was a net seller of stock by $-1.7B.
- Camber Capital Management has $1.1B in assets under management (AUM), dropping by -62.16%.
- Central Index Key (CIK): 0001444043
Tip: Access up to 7 years of quarterly data
Positions held by Camber Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Camber Capital Management
Camber Capital Management holds 25 positions in its portfolio as reported in the June 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) | 29.0 | $309M | -66% | 500k | 617.85 |
|
| Zimmer Holdings (ZBH) | 8.6 | $91M | -55% | 1.0M | 91.21 |
|
| Baxter International (BAX) | 8.1 | $86M | -50% | 2.9M | 30.28 |
|
| Humana (HUM) | 6.9 | $73M | -58% | 300k | 244.48 |
|
| CVS Caremark Corporation (CVS) | 6.8 | $72M | -53% | 1.1M | 68.98 |
|
| Globus Med Cl A (GMED) | 4.4 | $47M | -36% | 800k | 59.02 |
|
| Icon SHS (ICLR) | 4.1 | $44M | NEW | 300k | 145.45 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 4.1 | $43M | -28% | 250k | 172.60 |
|
| Merck & Co (MRK) | 3.7 | $40M | NEW | 500k | 79.16 |
|
| GSK Sponsored Adr Call Option (GSK) | 3.6 | $38M | 1.0M | 38.40 |
|
|
| Pfizer (PFE) | 3.4 | $36M | -83% | 1.5M | 24.24 |
|
| BioMarin Pharmaceutical (BMRN) | 3.1 | $33M | +20% | 600k | 54.97 |
|
| UnitedHealth (UNH) | 2.9 | $31M | NEW | 100k | 311.97 |
|
| Viatris (VTRS) | 2.3 | $25M | -63% | 2.8M | 8.93 |
|
| Brookdale Senior Living (BKD) | 1.4 | $15M | -65% | 2.2M | 6.96 |
|
| Zimvie (ZIMV) | 1.4 | $15M | -15% | 1.6M | 9.35 |
|
| Apellis Pharmaceuticals (APLS) | 1.4 | $15M | NEW | 850k | 17.31 |
|
| Myriad Genetics (MYGN) | 1.0 | $11M | -14% | 2.0M | 5.31 |
|
| Evolent Health Cl A (EVH) | 0.9 | $9.6M | -71% | 850k | 11.26 |
|
| Concentra Group Holdings Par Common Stock (CON) | 0.8 | $8.2M | -75% | 400k | 20.57 |
|
| Inogen (INGN) | 0.6 | $6.9M | 975k | 7.03 |
|
|
| Denali Therapeutics (DNLI) | 0.5 | $5.6M | -68% | 400k | 13.99 |
|
| Theravance Biopharma (TBPH) | 0.5 | $5.0M | -55% | 450k | 11.03 |
|
| Anaptysbio Inc Common (ANAB) | 0.3 | $2.8M | -83% | 125k | 22.20 |
|
| OraSure Technologies (OSUR) | 0.3 | $2.7M | 900k | 3.00 |
|
Past Filings by Camber Capital Management
SEC 13F filings are viewable for Camber Capital Management going back to 2010
- Camber Capital Management 2025 Q2 filed Aug. 14, 2025
- Camber Capital Management 2025 Q1 filed May 15, 2025
- Camber Capital Management 2024 Q4 filed Feb. 14, 2025
- Camber Capital Management 2024 Q3 filed Nov. 14, 2024
- Camber Capital Management 2024 Q2 filed Aug. 14, 2024
- Camber Capital Management 2024 Q1 filed May 15, 2024
- Camber Capital Management 2023 Q4 filed Feb. 14, 2024
- Camber Capital Management 2023 Q3 filed Nov. 14, 2023
- Camber Capital Management 2023 Q2 filed Aug. 14, 2023
- Camber Capital Management 2023 Q1 filed May 15, 2023
- Camber Capital Management 2022 Q4 filed Feb. 14, 2023
- Camber Capital Management 2022 Q3 filed Nov. 14, 2022
- Camber Capital Management 2022 Q2 filed Aug. 15, 2022
- Camber Capital Management 2022 Q1 filed May 16, 2022
- Camber Capital Management 2021 Q4 filed Feb. 14, 2022
- Camber Capital Management 2021 Q3 filed Nov. 15, 2021